Evaluating Ebola Therapies — The Case for RCTs

Properly designed randomized controlled trials of investigational Ebola drugs, with a control group receiving the best available supportive care, are critical to identifying urgently needed treatments for responding to the ongoing Ebola crisis and any future outbreaks. The worst Ebola epidemic in hi...

Full description

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 371; no. 25; pp. 2350 - 2351
Main Authors Cox, Edward, Borio, Luciana, Temple, Robert
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 18.12.2014
Subjects
Clinical trials
Ebola virus
Ebolavirus
Epidemics
Hemorrhagic Fever, Ebola - epidemiology
Hemorrhagic Fever, Ebola - mortality
Hemorrhagic Fever, Ebola - therapy
Humans
Medical treatment
Mortality
Outbreaks
Randomized Controlled Trials as Topic
United States > US
West Africa
Europe
Online AccessGet full text

Cover

More Information
Summary:Properly designed randomized controlled trials of investigational Ebola drugs, with a control group receiving the best available supportive care, are critical to identifying urgently needed treatments for responding to the ongoing Ebola crisis and any future outbreaks. The worst Ebola epidemic in history is ongoing. With the number of deaths from Ebola virus disease (EVD) already in the thousands and predicted to rise to tens of thousands, 1 the situation is tragic. No treatments have yet been shown to be safe and effective in patients with EVD. Some candidate therapies have shown benefit in animal models of infection, and others have shown activity against certain Ebola strains in cell culture, but concerns have been raised about possible toxicity of some of these agents. There is an urgent need to identify therapies that are effective and safe, and well-designed . . .
ISSN:0028-4793
1533-4406
DOI:10.1056/NEJMp1414145